One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving as later-line therapies to improve survival outcomes. The FDA has also ...

The Hatch-Waxman Act of 1984—which lowered barriers for smaller drug companies to introduce nonbrand versions of drugs whose patents had expired—was negotiated just as bigs like Johnson ...

The FDA has approved Johnson & Johnson’s drug Imaavy for the treatment of generalized myasthenia gravis, a chronic autoimmune neuromuscular disorder. The approval covers adults and pediatric patients ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...

The pharmaceutical industry maintains that the higher drug prices in the U.S. are essential ... to major pharmaceutical companies, including Johnson & Johnson (NYSE:JNJ). This leads us to the ...

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal in a late-stage study on ...

President Donald Trump signed an executive order aimed at reducing approval time for pharmaceutical plants to encourage ...

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...